Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From dosing protocols in Phase II trials to patent claims on deuterated psilocybin, Cybin’s SEC paperwork demands deep scientific and regulatory fluency. If you have ever scrolled through a 300-page prospectus searching for trial endpoints or waited for an 8-K that confirms a breakthrough-therapy meeting, you know the pain. Stock Titan solves it: our AI instantly converts dense disclosures into plain-English briefs, surfaces red-flag risks, and links each note back to the original page so you can verify facts in seconds. In short, consider this “Cybin SEC filings explained simply.”
Whether you need the full “Cybin annual report 10-K simplified” or want “Cybin quarterly earnings report 10-Q filing” highlights, we cover every form the moment it hits EDGAR. Real-time alerts track “Cybin Form 4 insider transactions real-time,” while interactive dashboards group every “Cybin insider trading Form 4 transactions” by executive and clinical milestone. Our engine delivers “Cybin 8-K material events explained,” maps R&D spend, and even decodes the “Cybin proxy statement executive compensation” tables so you see option grants in context. The AI-powered summaries update with each amendment, ensuring you are always reading the most current version.
Use the data the way professionals do: compare quarter-over-quarter trial costs, monitor “Cybin executive stock transactions Form 4” before key readouts, and share “Cybin earnings report filing analysis” with colleagues in one click. Still “understanding Cybin SEC documents with AI”? Our platform overlays definitions, creates custom peer benchmarks, and archives every footnote for audit trails. From first clinical IND to commercial launch, Stock Titan equips you with comprehensive coverage, expert commentary, and the clarity needed to make informed decisions faster than the market.
Cybin Inc. filed a Form D for a Rule 506(b) exempt securities offering to permit exercise of stock options that could generate up to $288,280 USD (CAD conversion provided). The securities are stock options exercisable at CAD$10.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The filing reports 0 amount sold to date, 288,280 USD remaining to be sold, and 10 total investors (also listed as 10 non-accredited investors). The offering is intended to last more than one year, minimum investment accepted is $0 USD, and no sales commissions or finders' fees are reported.
CYBIN INC. filed a Form D notice reporting a Regulation D exempt offering of options. The filing states a total potential offering amount of $637,404 USD (maximum proceeds from option exercises) and that $0 has been sold to date. The securities are stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The issuer selected Rule 506(b) as the exemption and indicated the offering may last more than one year. The Form D lists two investors in the offering, both non-accredited, and discloses no sales commissions or finders' fees and $0 proposed for payments to named executives or directors.
Point72 affiliates reported holding 1,606,317 common shares of Cybin Inc., representing 7.0% of the outstanding class as of June 30, 2025. The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons; each reports 0 sole voting or dispositive power and 1,606,317 shared voting and dispositive power. The statement clarifies that the shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, and that the filing is not an admission of beneficial ownership for Section 13 purposes. The signee is Jason M. Colombo, as authorized person, dated August 14, 2025.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
